Dans un article publié dans NATURE COMMUNICATIONS, des chercheurs provenant du monde entier, concluent à la dangerosité (mortalité) de l'hydroxychloroquine pour les patients atteints de Covid-19.
Parmi ces chercheurs, Professeur Ioanidis.
Lien de l'étude: https://www.nature.com/articles/s41467-021-22446-z?fbclid=IwAR2MVb7uPuqwmigybB2Wj28Uma_oXairwcfjh24NY0qEOwnO136bNLdW6TQ

Lire aussi les points faibles de l'étude:
"Our analysis has some limitations. First, although we adopted a comprehensive, systematic search strategy, our real-time initiative differs from traditional systematic reviews. We focused on collecting unpublished information, aiming to rapidly secure as much trial evidence as possible. We did not review individual trials, nor did we stratify results according to patient characteristics, and we have not collected information on other outcomes than mortality. Such analyses are planned in future publications using in-depth details disclosed in individual trial publications to come36,37,38. The exploratory subgroup analyses did not support the hypothesis that blinding/use of placebo is associated with the observed effect (the test for an interaction gives p = 0.15 and the OR is 0.88 with wide CIs 0.55–1.41, compatible with the overall effect); moreover, attrition was negligible (median 0%, IQR 0–0%; range 0–19.5%). A meta-epidemiological study shows little evidence that mortality results would be affected by lack of blinding, or problems in randomization and allocation concealment, in contrast to less objective outcomes39. Accordingly, we identified no relevant risk of bias across trials. Second, a majority of the potentially eligible trials were not available. Despite going far beyond the standard review of published evidence, we expect additional results from future trials on CQ to narrow the uncertainty of the treatment effect and possibly reveal benefits or harms not discernible based on the current evidence. We plan to perform an update when substantial additional evidence becomes available. Third, although this analysis intended to combine results from both inpatients and outpatients regardless of disease severity, trials enrolling patients with mild to moderate disease comprised a minority of the final sample size; many of which had zero or few events. Finally, although sensitivity analyses addressing model specifications were compatible with the main analysis, one combination (HKSJ model with SJ τ2 estimator) yielded substantially wider CIs. This combination gave disproportionately low weight to RECOVERY (15%) and we consider the main model (HKSJ with PM τ2 estimator) to be more valid in this situation."

❤Liens importants pour la chaîne:

??Rejoignez la chaîne Odyssee pour les debunkages.

- La chaîne
...
https://www.youtube.com/watch?v=WVefAyCnsjs